HSP90AA1 and psoriasis: Recently, two recent proof-of-concept studies revealed that orally administered HSP90 inhibitor (RGRN-305) led to marked improvements in psoriasis (open-label study; n=13) and hidradenitis suppurativa (randomised controlled trial; n=15) (18, 19).